Market revenue in 2023 | USD 236.1 million |
Market revenue in 2030 | USD 449.5 million |
Growth rate | 9.6% (CAGR from 2023 to 2030) |
Largest segment | Anti-vegf agents |
Fastest growing segment | Anti-VEGF agents |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Anti-Allergy, Anti-VEGF agents, Anti-inflammatory, Anti-glaucoma |
Key market players worldwide | Pfizer Inc, Alcon Inc, Novartis AG ADR, Bausch Health Companies Inc, Merck & Co Inc, Regeneron Pharmaceuticals Inc, AbbVie Inc, Bayer AG, Genentech, Nicox SA Share from reverse split, Coherus BioSciences Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to ophthalmic drugs market will help companies and investors design strategic landscapes.
Anti-vegf agents was the largest segment with a revenue share of 32.91% in 2023. Horizon Databook has segmented the Thailand ophthalmic drugs market based on anti-allergy, anti-vegf agents, anti-inflammatory, anti-glaucoma covering the revenue growth of each sub-segment from 2018 to 2030.
Thailand is highly dependent on medicinal plants and natural products for the development of medicine and medicinal products. There is a high prevalence of retinal diseases in the country, which has compelled research for the development of therapeutics for the same. Key players are focusing on collaborations and research to enhance the quality of life in the country.
For instance, in June 2021, Arctic Vision entered into a licensing agreement with Olympic Ophthalmic for the commercial distribution of iTEAR 100, a treatment for dry eye in South Korea and ASEAN countries, such as Thailand, Malaysia, Myanmar, Singapore, Vietnam, & China. Such initiatives are expected to help satisfy the demand for novel therapeutics.
Furthermore, rising initiatives to improve the healthcare infrastructure in the country are anticipated to propel the market growth in the country. To deal with the rising prevalence of retinal diseases, Thailand's Ministry of Public Health has established the Service Plan, a local health plan that incorporates 13 centers of excellence for certain specialties.
Horizon Databook provides a detailed overview of country-level data and insights on the Thailand ophthalmic drugs market , including forecasts for subscribers. This country databook contains high-level insights into Thailand ophthalmic drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account